01Cardiff Oncology reported Q3 2026 EPS of -$0.12, beating the consensus estimate of -$0.13 by $0.01 per share on November 12, 2026.
02Revenue reached $171.0K, significantly exceeding the estimate of $91.1K.
03The company has shown mixed earnings performance over four quarters, with Q1 2026 missing estimates by 38.5% while other quarters beat expectations.
04Cardiff Oncology remains unprofitable with negative earnings across all reported quarters.
Earnings Results
Cardiff Oncology (NASDAQ:CRDF) reported quarterly earnings results on November 12, 2026 that exceeded analyst expectations.
The company reported earnings per share of $-0.12, beating the consensus estimate of $-0.13 by $0.01 per share. Revenue came in at $171.0K, beating the estimate of $91.1K.
Company Overview
Cardiff Oncology's stock moved following the earnings release.
Cardiff Oncology's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Cardiff Oncology should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.